Actively Recruiting
Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
Led by Ruijin Hospital · Updated on 2024-12-03
500
Participants Needed
1
Research Sites
265 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate real-world treatment modalities and their corresponding effectiveness and safety in Chinese patients with marginal zone lymphoma, while also exploratively analyzing patient characteristics and health-related quality of life.
CONDITIONS
Official Title
Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be diagnosed as MZL
- Meet the treatment indications for MZL
You will not qualify if you...
- Any reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Ruijin Hospital
Shanghai, Shanghai Municipality, China, 200025
Actively Recruiting
Research Team
W
Weili Zhao
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here